Suppr超能文献

[三联免疫抑制疗法治疗重度溃疡性结肠炎]

[Triple immunosuppressive therapy in the treatment of severe ulcerative colitis].

作者信息

Castro B, Crespo J, García-Suárez C, Fábrega E, Casafont F, Pons-Romero F

机构信息

Servicio de Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, España.

出版信息

Gastroenterol Hepatol. 2004 Jan;27(1):1-5. doi: 10.1016/s0210-5705(03)70436-1.

Abstract

INTRODUCTION

Severe episodes of steroid-refractory ulcerative colitis (UC) were considered an indication for surgery until the introduction of new immunosuppressive agents such as cyclosporine.

OBJECTIVES

  1. To confirm the efficacy of intravenous cyclosporine in inducing remission in severe episodes of steroid-refractory UC; 2) To analyze the efficacy of triple immunosuppressive therapy with cyclosporine, azathioprine and prednisone in the maintenance of remission induced by intravenous cyclosporine.

PATIENTS AND METHOD

Fourteen patients diagnosed with a severe episode of steroid-refractory UC were treated with intravenous cyclosporine at a dose of 4 mg/kg/day. In all patients, after response was induced, this regimen was substituted by oral cyclosporine plus azathioprine at a dose of 2-2.5 mg/kg/day and decreasing doses of corticoids. Neoral cyclosporine was progressively reduced until discontinuation within 3 months, coinciding with a simultaneous decrease of oral steroids.

RESULTS

All patients showed response to intravenous cyclosporine with a significant reduction in the Truelove index calculated before and after treatment. After remission was induced, all patients followed triple immunosuppressive therapy for 3 months. In the follow-up for a mean of 24 months (range: 14-34) only two patients required admission for a new episode of UC and colectomy was finally indicated in only one. None of the 14 patients treated with cyclosporine showed severe adverse effects attributable to the drug.

CONCLUSIONS

Intravenous cyclosporine is a safe and effective alternative in the treatment of severe episodes of steroid-refractory UC. Early initiation of oral administration associated with azathioprine is useful in maintaining response, reducing subsequent relapses and the need for colectomy during the follow-up of these patients.

摘要

引言

在新的免疫抑制剂如环孢素出现之前,严重的类固醇难治性溃疡性结肠炎(UC)发作被视为手术指征。

目的

1)确认静脉注射环孢素在诱导严重的类固醇难治性UC发作缓解方面的疗效;2)分析环孢素、硫唑嘌呤和泼尼松三联免疫抑制疗法在维持静脉注射环孢素诱导的缓解方面的疗效。

患者与方法

14例被诊断为严重的类固醇难治性UC发作的患者接受了剂量为4mg/kg/天的静脉注射环孢素治疗。在所有患者中,诱导缓解后,该方案被替换为口服环孢素加硫唑嘌呤,剂量为2 - 2.5mg/kg/天,并逐渐减少皮质类固醇剂量。新山地明环孢素逐渐减量直至3个月内停药,同时口服类固醇剂量也相应减少。

结果

所有患者对静脉注射环孢素均有反应,治疗前后计算的 Truelove 指数显著降低。诱导缓解后,所有患者接受三联免疫抑制疗法3个月。在平均24个月(范围:14 - 34个月)的随访中,只有2例患者因新的UC发作需要住院,最终仅1例患者接受了结肠切除术。14例接受环孢素治疗的患者均未出现该药物所致的严重不良反应。

结论

静脉注射环孢素是治疗严重的类固醇难治性UC发作的一种安全有效的替代方法。早期开始联合硫唑嘌呤口服给药有助于维持疗效,减少后续复发以及这些患者随访期间结肠切除术的需求。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验